The DOJ's rescheduling of FDA-approved cannabis medicines could unlock banking access, tax credits, and mainstream investment for the struggling industry. Ananda Pharma plans a $10M–$20M raise, IGC Pharma eyes $50M for an Alzheimer's THC treatment, and Avicanna said rescheduling supports its IPO plans.
